Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis-Reference-Cited by-同舟云学术

Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis

Published:2023-07 Issue:4 Volume:10 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Frisch Esther S.¹,Häusler Darius¹,Weber Martin S.¹

Affiliation:

1. From the Department of Neuropathology (E.S.F., D.H., M.S.W.), University Medical Center; Department of Neurology (E.S.F., M.S.W.), University Medical Center; and Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP (D.H., M.S.W.), Göttingen, Germany.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200114

Reference16 articles.

1. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

3. Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients;Traub JW;J Neuroinflammation.,2019

4. Myeloid cells — targets of medication in multiple sclerosis

5. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Knowledge about Nonclassical Monocytes in Patients with Multiple Sclerosis, a Systematic Review;International Journal of Molecular Sciences;2024-07-05

2. A case study: ADEM-like lesions as a first clinical event in highly active multiple sclerosis;2024-04-19